CA2771352A1 - Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes - Google Patents

Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes Download PDF

Info

Publication number
CA2771352A1
CA2771352A1 CA2771352A CA2771352A CA2771352A1 CA 2771352 A1 CA2771352 A1 CA 2771352A1 CA 2771352 A CA2771352 A CA 2771352A CA 2771352 A CA2771352 A CA 2771352A CA 2771352 A1 CA2771352 A1 CA 2771352A1
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
c6alkyl
group
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2771352A
Other languages
English (en)
French (fr)
Inventor
Tesfaye Biftu
Ping Chen
Danqing Feng
Xiaoxia Qian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of CA2771352A1 publication Critical patent/CA2771352A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2771352A 2009-09-02 2010-08-23 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes Abandoned CA2771352A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23924209P 2009-09-02 2009-09-02
US61/239,242 2009-09-02
US26227809P 2009-11-18 2009-11-18
US61/262,278 2009-11-18
PCT/US2010/046270 WO2011028455A1 (en) 2009-09-02 2010-08-23 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes

Publications (1)

Publication Number Publication Date
CA2771352A1 true CA2771352A1 (en) 2011-03-10

Family

ID=43649576

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2771352A Abandoned CA2771352A1 (en) 2009-09-02 2010-08-23 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes

Country Status (12)

Country Link
US (1) US8455533B2 (enExample)
EP (1) EP2473047B1 (enExample)
JP (1) JP5734981B2 (enExample)
KR (1) KR20120092096A (enExample)
CN (1) CN102595897A (enExample)
AU (1) AU2010289871B2 (enExample)
BR (1) BR112012004335A8 (enExample)
CA (1) CA2771352A1 (enExample)
IN (1) IN2012DN00721A (enExample)
MX (1) MX2012002633A (enExample)
RU (1) RU2550508C2 (enExample)
WO (1) WO2011028455A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103256A1 (en) 2010-02-22 2011-08-25 Merck Sharp & Dohme Corp. Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
US8980929B2 (en) 2010-05-21 2015-03-17 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
WO2012078448A1 (en) 2010-12-06 2012-06-14 Schering Corporation Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
MY159058A (en) 2011-02-25 2016-12-15 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
AU2012267556B9 (en) 2011-06-09 2017-05-11 Rhizen Pharmaceuticals Sa Novel compounds as modulators of GPR-119
WO2013003249A1 (en) 2011-06-29 2013-01-03 Merck Sharp & Dohme Corp. Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor
EP2729468A4 (en) 2011-07-05 2015-03-18 Merck Sharp & Dohme Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
WO2013122920A1 (en) 2012-02-17 2013-08-22 Merck Sharp & Dohme Corp. Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US9156848B2 (en) 2012-07-23 2015-10-13 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-IV inhibitors
US9315508B2 (en) 2012-07-23 2016-04-19 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-IV inhibitors
TWI500613B (zh) 2012-10-17 2015-09-21 Cadila Healthcare Ltd 新穎之雜環化合物
CN105085528A (zh) * 2014-05-15 2015-11-25 成都贝斯凯瑞生物科技有限公司 作为二肽基肽酶-iv抑制剂的氨基四氢吡喃衍生物
EP3159344B1 (en) 2014-06-17 2023-09-20 Sichuan Haisco Pharmaceutical Co., Ltd. Amino pyranoid ring derivative and composition and use thereof
US9862725B2 (en) 2014-07-21 2018-01-09 Merck Sharp & Dohme Corp. Process for preparing chiral dipeptidyl peptidase-IV inhibitors
CN105985357A (zh) * 2015-02-12 2016-10-05 北京赛林泰医药技术有限公司 取代的氨基六元饱和杂脂环类长效dpp-iv抑制剂
TWI681962B (zh) * 2015-08-26 2020-01-11 大陸商四川海思科製藥有限公司 胺基六員環類衍生物及其在醫藥上的應用
MA48803A (fr) 2017-05-31 2020-04-08 Chemocentryx Inc Cycles 6-5 fusionnés utilisés en tant qu'inhibiteurs de c5a
CN107459501B (zh) * 2017-08-22 2020-06-09 钟桂发 一种奥格列汀的手性中间体的制备方法
CA3085946A1 (en) 2017-12-22 2019-06-27 Chemocentryx, Inc. Diaryl substituted 6,5-fused ring compounds as c5ar inhibitors
CN116919952A (zh) * 2018-02-06 2023-10-24 四川海思科制药有限公司 一种氨基吡喃衍生物的组合物
US20190300526A1 (en) 2018-04-02 2019-10-03 Chemocentryx, Inc. PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS
KR102131359B1 (ko) * 2018-09-07 2020-07-07 오토텔릭바이오 주식회사 안정성이 향상된 의약 조성물

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5232929A (en) 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
DE19616486C5 (de) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
WO1998039342A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
WO1998039344A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
ATE253073T1 (de) 1997-03-07 2003-11-15 Metabasis Therapeutics Inc Neue benzimidazol inhibitoren der fructose-1,6- bisphosphatase
WO1999001423A1 (en) 1997-07-01 1999-01-14 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
KR20010052302A (ko) 1998-05-04 2001-06-25 바바라 피. 월너 조혈 자극
EP1112275B9 (en) 1998-09-09 2004-03-10 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
GB9906715D0 (en) 1999-03-23 1999-05-19 Ferring Bv Compositions for promoting growth
KR20020014797A (ko) 1999-05-17 2002-02-25 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 글루카곤 길항제/역 아고니스트
WO2002008188A1 (en) 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
KR20030096227A (ko) 2000-10-27 2003-12-24 프로비오드룩 아게 신경 및 신경정신 질환의 치료방법
AU2002240235B2 (en) 2001-01-30 2006-07-06 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
US7183290B2 (en) 2001-06-27 2007-02-27 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
DK1537078T3 (da) 2002-08-29 2010-08-02 Merck Sharp & Dohme Indoler med anti-diabetisk aktivitet
CA2495915A1 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
US7192922B2 (en) 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
US7319170B2 (en) 2003-01-17 2008-01-15 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzensulfonmide derivatives
US20050065144A1 (en) 2003-09-08 2005-03-24 Syrrx, Inc. Dipeptidyl peptidase inhibitors
CN101014598B (zh) 2004-06-21 2012-06-13 默沙东公司 作为用于治疗或预防糖尿病的二肽基肽酶-ⅳ抑制剂的氨基环己烷化合物
WO2006020372A2 (en) 2004-07-23 2006-02-23 Neose Technologies, Inc. Enzymatic modification of glycopeptides
US7718667B2 (en) 2004-09-28 2010-05-18 Merck Sharp & Dohme Corp. Fused aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
CA2582447C (en) 2004-10-01 2012-04-17 Merck & Co., Inc. Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
KR20070068407A (ko) 2004-10-25 2007-06-29 노파르티스 아게 Ｄｐｐ―ｉｖ 억제제, ｐｐａｒ 항당뇨병제 및메트포르민의 조합물
ATE527259T1 (de) 2004-11-29 2011-10-15 Merck Sharp & Dohme Kondensierte aminopiperidine als dipeptidylpeptidase-iv-inhibitoren zur behandlung oder prävention von diabetes
BRPI0519585A2 (pt) 2004-12-20 2009-02-25 Hoffmann La Roche compostos de fàrmula i; processo para a fabricaÇço de compostos de fàrmula i; composiÇÕes farmacÊuticas; mÉtodo para o tratamento e/ou profilaxia de doenÇas que estço associadas com a dpp-iv e usos destes compostos
US7411093B2 (en) 2004-12-20 2008-08-12 Hoffman-La Roche Inc. Aminocycloalkanes as DPP-IV inhibitors
EP1702916A1 (en) 2005-03-18 2006-09-20 Santhera Pharmaceuticals (Schweiz) GmbH DPP-IV inhibitors
CN103275083A (zh) 2005-05-25 2013-09-04 默沙东公司 用于糖尿病治疗或者预防的作为二肽基肽酶-iv抑制剂的氨基环己烷
WO2006134340A2 (en) 2005-06-13 2006-12-21 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
ATE549926T1 (de) 2005-08-26 2012-04-15 Merck Sharp & Dohme Kondensierte aminopiperidine als dipeptidylpeptidase-iv-inhibitoren zur behandlung oder prävention von diabetes
EP1962601B1 (en) 2005-12-14 2014-10-15 Merck Sharp & Dohme Corp. Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
CA2636757A1 (en) 2006-01-25 2007-08-02 Tesfaye Biftu Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US7910596B2 (en) 2006-02-15 2011-03-22 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
AU2007221366B2 (en) 2006-02-22 2012-08-23 Msd Italia S.R.L. Oxyntomodulin derivatives
CN101443356A (zh) 2006-03-20 2009-05-27 默克公司 神经介肽u受体激动剂及其用途
CN101410400B (zh) * 2006-03-28 2012-09-05 默沙东公司 作为用于糖尿病治疗或者预防的二肽基肽酶-ⅳ抑制剂的氨基四氢吡喃
TW200806669A (en) 2006-03-28 2008-02-01 Merck & Co Inc Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
AU2007254357B2 (en) 2006-05-16 2011-07-21 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
CN101535341A (zh) 2006-07-18 2009-09-16 森托科尔奥索生物科技公司 人glp-1模拟体、组合物、方法和用途
JP5232160B2 (ja) 2006-11-14 2013-07-10 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖインヒビターとしての三環式芳香族複素環化合物
EA017849B1 (ru) 2007-02-15 2013-03-29 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Соагонисты глюкагоновых/glp-1-рецепторов
CA2691010A1 (en) 2007-06-28 2008-12-31 Merck Frosst Canada Ltd. Substituted fused pyrimidines as antagonists of gpr105 activity
JP2010533712A (ja) 2007-07-19 2010-10-28 メルク・シャープ・エンド・ドーム・コーポレイション 抗糖尿病化合物としてのベータカルボリン誘導体
WO2009014676A1 (en) 2007-07-23 2009-01-29 Merck & Co., Inc. Novel crystalline form of a dihydrochloride salt of a dipeptidyl peptidase-iv inhibitor
US8653059B2 (en) 2007-08-21 2014-02-18 Merck Sharp & Dohme Corp. Heterocyclic compounds as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2009042053A2 (en) 2007-09-21 2009-04-02 Merck & Co., Inc. Neuromedin u receptor agonists and uses thereof
JP2012505231A (ja) 2008-10-08 2012-03-01 ブリストル−マイヤーズ スクイブ カンパニー アゾロピロロンメラニン凝集ホルモン受容体−１アンタゴニスト
JO2870B1 (en) * 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
US8716482B2 (en) 2009-09-25 2014-05-06 Merck Sharp & Dohme Corp. Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes

Also Published As

Publication number Publication date
AU2010289871A1 (en) 2012-04-26
MX2012002633A (es) 2012-04-20
EP2473047A4 (en) 2013-02-13
US20120149734A1 (en) 2012-06-14
KR20120092096A (ko) 2012-08-20
CN102595897A (zh) 2012-07-18
RU2012112471A (ru) 2013-10-10
IN2012DN00721A (enExample) 2015-06-19
EP2473047A1 (en) 2012-07-11
EP2473047B1 (en) 2014-08-13
BR112012004335A8 (pt) 2016-06-21
JP5734981B2 (ja) 2015-06-17
AU2010289871B2 (en) 2014-07-10
US8455533B2 (en) 2013-06-04
RU2550508C2 (ru) 2015-05-10
BR112012004335A2 (pt) 2015-09-08
WO2011028455A1 (en) 2011-03-10
JP2013503864A (ja) 2013-02-04

Similar Documents

Publication Publication Date Title
CA2742783C (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
AU2010289871B2 (en) Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
HK1187343A (en) Combination drugs comprising aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
HK1154849B (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
HK1187344A (en) Combination drugs comprising aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
HK1187342A (en) Combination drugs comprising aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150729

FZDE Discontinued

Effective date: 20170823